1. 844 Immunomodulatory activity of epigenetic drugs combinations in mesothelioma: laying the ground for new immunotherapeutic strategies. (10th December 2020) Authors: Cannito, Sara; Biology, Health; Cutaia, Ornella; Fazio, Carolina; Lofiego, Maria Fortunata; Piazzini, Francesca; Solmonese, Laura; Calabrò, Luana; Maio, Michele; Covre, Alessia Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A503 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 844 Immunomodulatory activity of epigenetic drugs combinations in mesothelioma: laying the ground for new immunotherapeutic strategies. (9th November 2020) Authors: Cannito, Sara; Biology, Health; Cutaia, Ornella; Fazio, Carolina; Lofiego, Maria Fortunata; Piazzini, Francesca; Solmonese, Laura; Calabrò, Luana; Maio, Michele; Covre, Alessia Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A896 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Issue 4 (April 2022) Authors: Kindler, Hedy L; Novello, Silvia; Bearz, Alessandra; Ceresoli, Giovanni L; Aerts, Joachim G J V; Spicer, James; Taylor, Paul; Nackaerts, Kristiaan; Greystoke, Alastair; Jennens, Ross; Calabrò, Luana; Burgers, Jacobus A; Santoro, Armando; Cedrés, Susana; Serwatowski, Piotr; Ponce, Santiago; Van Me... Journal: Lancet oncology Issue: Volume 23:Issue 4(2022) Page Start: 540 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Issue 11 (November 2018) Authors: Barlesi, Fabrice; Vansteenkiste, Johan; Spigel, David; Ishii, Hidenobu; Garassino, Marina; de Marinis, Filippo; Özgüroğlu, Mustafa; Szczesna, Aleksandra; Polychronis, Andreas; Uslu, Ruchan; Krzakowski, Maciej; Lee, Jong-Seok; Calabrò, Luana; Arén Frontera, Osvaldo; Ellers-Lenz, Barbara; Bajars, M... Journal: Lancet oncology Issue: Volume 19:Issue 11(2018) Page Start: 1468 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features. Issue 4 (8th May 2022) Authors: Di Giacomo, Anna M.; Guarnieri, Andrea; Tripodi, Sergio A.; Maccari, Marta; Mancianti, Nicoletta; Guido, Garosi; Rossi, Giulia; Daffinà, Maria Grazia; Calabrò, Luana; Valente, Monica; Maio, Michele Journal: Journal of immunotherapy Issue: Volume 45:Issue 4(2022) Page Start: 217 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Challenges in lung cancer therapy during the COVID-19 pandemic. Issue 6 (June 2020) Authors: Calabrò, Luana; Peters, Solange; Soria, Jean-Charles; Di Giacomo, Anna Maria; Barlesi, Fabrice; Covre, Alessia; Altomonte, Maresa; Vegni, Virginia; Gridelli, Cesare; Reck, Martin; Rizvi, Naiyer; Maio, Michele Journal: Lancet Issue: Volume 8:Issue 6(2020) Page Start: 542 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Issue 4 (April 2015) Authors: Calabrò, Luana; Morra, Aldo; Fonsatti, Ester; Cutaia, Ornella; Fazio, Carolina; Annesi, Diego; Lenoci, Marica; Amato, Giovanni; Danielli, Riccardo; Altomonte, Maresa; Giannarelli, Diana; Di Giacomo, Anna Maria; Maio, Michele Journal: Lancet Issue: Volume 3:Issue 4(2015) Page Start: 301 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Issue 4 (April 2015) Authors: Calabrò, Luana; Morra, Aldo; Fonsatti, Ester; Cutaia, Ornella; Fazio, Carolina; Annesi, Diego; Lenoci, Marica; Amato, Giovanni; Danielli, Riccardo; Altomonte, Maresa; Giannarelli, Diana; Di Giacomo, Anna Maria; Maio, Michele Journal: Lancet Issue: Volume 3:Issue 4(2015) Page Start: 301 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Issue 6 (June 2021) Authors: Yap, Timothy A; Nakagawa, Kazuhiko; Fujimoto, Nobukazu; Kuribayashi, Kozo; Guren, Tormod Kyrre; Calabrò, Luana; Shapira-Frommer, Ronnie; Gao, Bo; Kao, Steven; Matos, Ignacio; Planchard, David; Chatterjee, Arkendu; Jin, Fan; Norwood, Kevin; Kindler, Hedy L Journal: Lancet Issue: Volume 9:Issue 6(2021) Page Start: 613 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT). (August 2017) Authors: Russo, Vincenzo; Amadori, Alberto; Bregni, Marco; Calabrò, Luana; Colombo, Mario Paolo; Di Nicola, Massimo; Ferrucci, Pier Francesco; Proietti, Enrico; Maio, Michele; Bellone, Matteo Journal: Cytokine & growth factor reviews Issue: Volume 36(2017) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗